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ABSTRACT
INTRODUCTION: Antimicrobial peptides (AMPs) are a growing class of natural and synthetic compounds 
with a wide spectrum of targets including viruses, bacteria, fungi, and parasites. 
AIM: The aim of the present review was to make an overview of the available literature on the pharmacological 
activities of these peptides, focusing on lactoferricin and lactoferricin analogues.
MATERIALS AND METHODS: To achieve this aim, information from databases, such as PubMed, Google 
Scholar and ResearchGate was searched and summarized.
RESULTS: Antimicrobial peptides (AMPs) are considered a promising alternative to the antibiotics used 
nowadays. They have drawn a special attention in the fight against infections caused by antibiotic-resistant 
bacterial strains. Lactoferricin is the most studied AMP derived from milk protein. Lactoferricin (Lfcin) is 
a fragment of the ferro-chelate complex of the bovine protein lactoferrin (Lf). The amphipathic and cationic 
properties of Lfcin account for its broad spectrum antimicrobial activity. Lfcin also manifests potential 
antiviral, immunomodulatory, antitumor and anti-inflammatory properties. Shorter analogues of Lfcins 
have been synthesized with a broad spectrum of activities and enhanced pharmacokinetic properties.
CONCLUSION: Lactoferricin and its analogues are a good demonstration that it is possible to design and 
obtain synthetic peptides with enhanced pharmacological activities.
Keywords: antimicrobial peptides, lactoferricin, lactoferricin analogues, pharmacological activities
INTRODUCTION
The increasing level of resistance to the antibi-
otics used nowadays is a serious threat to the public 
health. A lot of patients are hospitalized as a result of 
infections caused by resistant bacteria, such as E. coli, 
K. pneumoniae, P. aeruginosa, methicillin-resistant 
S. aureus, etc. (1). Antimicrobial peptides (AMPs) 
have received special attention as a possible alterna-
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of the bovine protein lactoferrin (Lf). When Lf en-
ters the gastrointestinal tract, it undergoes hydrolysis 
by the enzyme pepsin and turns into Lfcin (14). Lfcin 
can be found in humans (LfcinH), in cattle (LfcinB) 
and mice (LfcinM) (15). 
Lfcin contains both hydrophobic and hydro-
philic residues (16). It contains aromatic amino acids 
such as tryptophan (Trp) and phenylalanine (Phe), 
as well as some basic amino acids, such as arginine 
(Arg) and lysine (Lys). Lfcin contains two cysteine 
residues which make up an internal disulfide bridge 
and ensure the amphipathic properties of the peptide 
(Таble 1) (15). 
Lactoferricin Antimicrobial Activity
Lfcin is a more potent antimicrobial agent in 
comparison with Lf (15) and its antimicrobial effect 
is due to its cationic and amphipathic properties (17-
20). Lfcin binds to negatively charged components 
of bacterial membranes and disrupts the membrane 
integrity (21). The amino acid sequence in different 
types of Lfcin is related to the antimicrobial activi-
ty (Таble 1).
A study of Vorland et al. (15) has shown that Lf-
cinB has the lowest minimal inhibitory concentra-
tion (MIC) and is the only Lfcin that is active against 
Е. coli and S. aureus. LfcinB demonstrates a stronger 
antimicrobial activity in comparison with LfcinH 
and LfcinM due to its greater hydrophobicity and the 
higher positive charge (15). 
LfcinB-derived peptide (LfB17-41) has dem-
onstrated activity against E. coli, S. aureus, C. albi-
cans, C. tropicalis, C. neoformans, HCMV, HSV (13). 
The synthetic bovine Lfcin analogue (LfB17-31 or Lf-
cinB17-31) acts against E. coli, S. aureus, B. subtilis, S. 
cerevisiae, P. digitatum, P. italicum, P. expansum, Al-
ternaria spp., A. nidulans, B. cinerea, F. oxysporum 
tive to fight against infections caused by antibiotic-
resistant bacterial strains (2).
In the present paper, the pharmacological ac-
tivities of synthetic peptides derived from Lactoferri-
cin (Lfcin) are summarized on the basis of informa-
tion from databases, such as PubMed, Google Schol-
ar and ResearchGate.
Antimicrobial Peptides (AMPs)
AMPs can be isolated from both prokaryotes 
(bacteria) and eukaryotes (fungi, plants, insects and 
animals) (3). They are oligopeptides that contain a 
different number of amino acids (size from 2-10 kDa) 
and demonstrate amphipathic properties. They usu-
ally have a positive charge (that ranges from +2 tо +9) 
due to the abundance of the basic amino acids such 
as lysine (Lys) and arginine (Arg). This allows their 
selective binding to the negatively charged biological 
membranes of microorganisms (4,5). АМРs contain 
also other specific amino acids such as proline (Pro) 
(6), tryptophan (Trp) (7,8), glycine (Gly) (9,10), cyste-
ine (Cys) (11) or histidine (His) (12).
Trp-rich AMPs (TrAMPs) are of a particular 
interest. The amino acid Trp has unique biochemical 
properties that account for the strong antimicrobi-
al properties of TrAMPs. Representatives of TrAMPs 
are indolicidin, tritrpticin and Lfcin. Indolicidin pos-
sesses activity against E. coli, S. aureus, P. aerugino-
sa, S. typhimurium, S. epidermidis, T. beigelii, C. albi-
cans, S. cerevisiae, HSV and G. lamblia (13). Tritrpti-
cin is active against E. coli, S. aureus, P. aeruginosa, 
K. pneumoniae, S. epidermidis, Streptococcus group 
D, P. mirabilis and A. fumigatus (13).
Lactoferricin Structure
Lfcin is derived from milk protein. It is a 
25-amino acid fragment of the ferro-chelate complex 




Таble 1. Amino acid sequences of bovine, mouse and human Lfcins. The highlighted residues (bold) present the avail-
ability of a disulfide bond between two cysteine residues in each peptide. Adapted from Vorland et al. (15)
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and M. grisea. LfcinB20-25, another synthetic bovine 
Lfcin analogue, has a spectrum of activity including 
E. coli, B. subtilis, S. cerevisiae, P. digitatum, P. ita-
licum, P. expansum, Alternaria spp., A. nidulans, B. 
cinerea, F. oxysporum and M. grisea. The spectra of 
other bovine Lfcin analogues are respectively E. coli, 
S. aureus, P. aeruginosa for LfB17-27 and E. coli, S. 
aureus for LfB4-14.
Lactoferricin Antiviral Activity 
HSV infection is one of the most frequent viral 
infections in people. Its treatment started back in the 
1970s with aciclovir. Research on the mechanism of 
action and the knowledge about the anti-HSV activ-
ity of Lf/Lfcin have been successfully applied in de-
signing new, more specific anti-HSV agents (22). Lf 
competes for the heparan sulfate attachment sites in 
the host cells. As a result, viral entry inhibition and 
Peptide and Origin Immunomodulatory Effects
Bovine lactoferrin
(LfB)
↓LPS-induced TNF-α in osteoblasts
↓flagellin-induced IL-1β in osteoclasts
↓TNF-α, IL-6, and GM-CSF in squamous cell carcinoma cell line
IL-6 in LPS-treated THP-1 cells
↑phagocytosis of BMDM, THP-1 and U937 cells, and neutrophils 
↓oxidative stress/apoptosis in U937 cells 
↑CD40 in RAW 264.7 cells 
↑IL-12 in peritoneal macrophages 
↓T-cell proliferation and secretion of IL-5
↓TNF- α and IL-6 in blood of E.coli infected mice
↓TNF- α and IL-6 in carrageenan-induced inflammation in rat feet
Bovine lactoferricin
(LfcinB)
↓iNOS and IL-6 in nucleus pulposus cells of human intervertebral disc
↓IL-1β, IL-6, iNOS, TLR-2 in chondrocytes 
↑IL-4 and IL-10 in chondrocytes 
↑IL-10 in articular cartilage
↓IL-6 in LPS-stimulated THP-1 cells
↑thymidine uptake by mitogen-activated splenocytes
Human lactoferrin
(LfH)
↓ICAM, E-selectin and TNF-α in HUVECs 
↑IL-8, CXCL10, IL-10 in human DCs 
↓TNF-α in macrophages
↓PGE2 secretion by breast milk macrophages 
↓IFNγ in human DCs
↓IL6 in LPS-stimulated THP-1 cells
↓inflammation in dextran sulfate model of colitis in mice




↓myeloperoxidase activity in primary human macrophages
↑IL-10 in primary human macrophages 
↓TNF-α in LPS-stimulated human mononuclear cells 
↓TNF-α in macrophages stimulated with lipid A
Таble 2. Mechanisms of the immunomodulatory and anti-inflammatory effects of bovine and human Lf and Lfcin (36) 
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suppression of the further HSV infection of the host 
cells occur (23-26). Lfcins display antiviral activi-
ty against other viruses, such as HPV (27) and HIV 
(28).
Lactoferricin Antitumor Activity
Lfcins display a highly selective cytotoxic effect 
against tumor cells. They target the membrane an-
ionic phosphatidylserine on the cellular membrane 
of cancer cells and disrupt the membrane (29). Apart 
from this, the peptides which translocate to the cy-
tosol, interact with the mitochondrial membrane 
due to its high content of negatively charged lipids. 
As a consequence, they disrupt the metabolism and 
may induce apoptosis. Apoptosis at a late stage is in-
duced by LfcinsB by inhibition of autophagy (30). Bo-
vine Lf and LfcinsB exert antitumor activities on hu-
man colorectal cancer cells (HT-29) (31). LfcinB in-
duces apoptosis in human monocytic leukemia cell 
lines THP-1 (32). It can be attributed to the intracel-
lular free radical production and activation of Ca2+/
Mg2+-dependent endonucleases (33). In vivo tests 
have shown that bovine lactoferrin (LfB) and LfcinB 
suppress tumor growth and inhibit tumor metasta-
ses in mice (34). Apart from this, LfcinB has been re-
ported to increase the sensitivity to anticancer drugs 
(35). This results from LfcinB-induced inhibition of 
glutathione S-transferase P1 isoform (GSTP1), which 
is overexpressed in some cancer cells and is responsi-
ble for their resistance to anticancer drugs. 
Lactoferricin Immunomodulatory and Anti-
Inflammatory Activities 
Lf and Lfcin are peptides that are able to act as 
immunomodulators and anti-inflammatory agents 
as well (Table 2) (36). 
The most in-depth research of the immuno-
modulatory effect of these peptides refers to their 
ability to suppress the proinflammatory response 
in vivo and in vitro. Lactoferrin modulates the mi-
gration, maturation and function of immune cells 
(37-39).  
Research on human Lf (LfH) has shown the 
importance of this peptide as an anti-inflammatory 
agent. A study conducted by Haversen et al. has con-
vincingly demonstrated the importance of LfH in re-
ducing the IL-1β-provoked inflammatory response 
in mice that suffer from in acute dextran sulphate-
induced colitis (40).
LfcinB is also an effective anti-inflammato-
ry and anti-catabolic agent. It can regulate the anti-
inflammatory cytokines IL-6, IL-10, IL-11 and IL-4 
(36,41). Investigations of LfcinH have also shown its 
ability to regulate cytokines (IL-10) and to reduce the 
production of TNF-α in macrophages induced by 
bacteria (42-44).
Some applications of Lfcins on the basis of their 
immunomodulatory, antimicrobial, antiviral and 
antitumor activities are summarized in Table 3 (15).
Field Application Target Object 
Preclinical 
Skin cancer - Mouse
Keratitis Ps. aeruginosa, S. aureus Mouse
Herpes simplex virus HSV-2 line Mouse
Veterinary
Atopic dermatitis - Dog
Otitis externa Bacteria and yeast Dog
Bovine mastitis Staphylococci, Streptococci, E. coli Cow
Dietary supplementation Antibiotic alternative, E. coli Weaned piglet
Food
Spoilage Pseudomonas fluorescens Ground beef
Spoilage Pseudomonas spp. Vegetable
Spoilage Penicillium digitatum Mandarins
Spoilage Lactic acid bacteria, Dekkera bruxellensis Wine
Spoilage Pseudomonas spp., E. coli Cheese
Таble 3. Applications of Lfcins; adapted from Hao et al., 2018 (15) 
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Synthesis and Antimicrobial Activity of Lacto-
ferricin Analogues
The design of peptides with potential pharma-
cological and therapeutic application is based on the 
synthesis of a series of structurally similar substanc-
es and tracing the relationship between structure and 
activity in standard pharmacological tests with the 
help of which their clinical efficacy can be predicted.
Peptides tend to draw a greater attention as po-
tential drugs. Nevertheless, their application is lim-
ited because of some physicochemical characteris-
tics. Such are the relatively high molecular mass and 
hydrophilicity, which lead to a limited penetration 
through biological membranes, as well as the deg-
radation by peptidases and instability in the blood-
stream. These properties determine a low bioavail-
ability and short plasma half-lives. Among the chem-
ical transformations of peptides, cyclization, the in-
corporating of D-amino acids or non-protein ami-
no acids are of practical significance. Thus, the mod-
ified oligopeptides easily turn into derivatives with 
enhanced pharmacokinetic properties.
Recently, scientists have paid a great attention to 
new chemical structures which have biological activ-
ities. Analogues of the natural AMPs are being syn-
thesized by incorporating both natural and non-nat-
ural amino acid sequences in their structure. Thus, 
shorter and more effective AMP derivatives are ob-
tained. There is evidence already that AMP deriv-
atives are able to effectively destroy pathogenic mi-
croorganisms (45). Cationic AMPs bind preferential-
ly to the negatively charged phospholipid bilayer of 
bacterial membranes resulting in formation of trans-
membrane pores and ultimately bacterial cell death 
(19). The lack of specific receptors makes it difficult 
for bacteria to develop resistance to the peptide (46). 
Short peptides are supposed to demonstrate high-
er antimicrobial activities (45,47). The most impor-
tant structural requirement for the manifestation of 
a high antimicrobial activity of such short peptides is 
the content of minimum 3 amino acid residues con-
taining the amino acids Arg and Trp. Short peptides, 
which do not meet the above-mentioned require-
ment, demonstrate a much lower activity. Lfcins are 
one such example. The antimicrobial activity of Lf-
cin analogues as modular systems has been explored. 
Research is being conducted to find out which mo-
lecular characteristics are important for the antimi-
crobial activity. Data is available for observed anti-
bacterial activity of the 25 amino acid fragment 17-
41 of the ripe protein LfB (LfcinB). In 1996, it was 
shown that its undecapeptide segment 20-30 (LfB20-
30) has a similar antimicrobial activity to that of the 
25 amino acid fragment. The antibacterial activity 
of LfB20-30 is enhanced by modification that sub-
stitutes all lysine amino acid residues with arginine. 
The activity of the homologous undecapeptide seg-
ments 17-27 from LfcinB can be improved later with 
the incorporation of tryptophan amino acid resi-
dues (14). Even shorter Lfcin derivatives also man-
ifest a good antibacterial activity. The active cen-
ter of LfcinB is a hexapeptide corresponding to the 
20-25 fragment. The amidation of the C-terminal of 
this peptide influences the potentiation of its activi-
ty in relation to E. coli (Gram-negative) and S. aureus 
(Gram-positive) bacteria (48).
CONCLUSION 
The natural antimicrobial peptides can offer 
a good alternative to the conventional antibiotics, 
which have become highly ineffective against resis-
tant bacterial strains. Lfcins have proven to be good 
antimicrobial agents (in vitro). Antiviral, immuno-
modulatory and antitumor activities of these pep-
tides have also been established in vitro and in vivo. 
There is a possibility of potentiating the antimicro-
bial activity through synthesizing shorter analogues 
of Lfcins, which are good antimicrobial agents with a 
proven ability to avoid developing resistance to them.
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